Abstract
The formation of urinary stone, urolithiasis, is one the oldest known disease affecting human throughout different civilizations and times. The exact pathophysiological mechanism of urolithiasis is not yet clear, as these calculi are of various types and too complex for simple understanding. A single theory cannot explain its formation; therefore, different theories are presented in various times for its explanation like free particle, fixed particle, Randall’s plaque theory. In addition, various factors and components are identified that play an important role in the formation of these urinary calculi. In this review, composition of kidney stones, its prevalence/incidence, explanation of pathophysiological mechanisms and role of various factors; urinary pH, uric acid, parathyroid hormone, citrate, oxalate, calcium and macromolecules; osteopontin, matrix Gla protein, kidney injury molecules, urinary prothrombin fragment-1, Tamm–Horsfall protein, inter-α-inhibitors, have been discussed in detail.
Similar content being viewed by others
References
Lopez M, Hoppe B (2010) History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 25(1):49–59
Lyu J, Wu R (2014) A brief history of recognition on urolithiasis before medieval period. Zhonghua Yi Shi Za Zhi 44(1):36–39
Tefekli A, Cezayirli F (2013) The history of urinary stones: in parallel with civilization. Sci World J 2013:423964
Cloutier J et al (2015) Kidney stone analysis: “give me your stone, I will tell you who you are!”. World J Urol 33:157–169
Lemann J Jr (1993) Composition of the diet and calcium kidney stones. N Engl J Med 328(12):880–882
Evan AP (2010) Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 25(5):831–841
Almazroui M et al (2012) Recent climate change in the Arabian Peninsula: seasonal rainfall and temperature climatology of Saudi Arabia for 1979–2009. Atmos Res 111:29–45
Lieske JC et al (2006) Diabetes mellitus and the risk of urinary tract stones: a population-based case–control study. Am J Kidney Dis 48:897–904
Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21:257–264
Rezaee ME et al (2017) Association between multiple chronic conditions and urolithiasis. Int Urol Nephrol 49(8):1361–1367
Polat EC et al (2015) Relationship between calcium stone disease and metabolic syndrome. Urol J 12:2391–2395
Saucier NA et al (2010) Risk factors for CKD in persons with kidney stones: a case–control study in Olmsted County, Minnesota. Am J Kidney Dis 55(1):61–68
Grover PK, Kim DS, Ryall RL (2002) The effect of seed crystals of hydroxyapatite and brushite on the crystallization of calcium oxalate in undiluted human urine in vitro: implications for urinary stone pathogenesis. Mol Med 8(4):200–209
Kirkali Z et al (2015) Urinary stone disease: progress, status, and needs. Urology 86(4):651–653
Soucie JM et al (1994) Demographic and geographic variability of kidney stones in the United States. Kidney Int 46(3):893–899
Brikowski TH, Lotan Y, Pearle MS (2008) Climate-related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci USA 105(28):9841–9846
Pak CY (1998) Kidney stones. Lancet 351(9118):1797–1801
Stamatelou KK et al (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63(5):1817–1823
Hussain M et al (2009) Management of stone disease: 17 years experience of a stone clinic in a develo** country. J Pak Med Assoc 59(12):843–846
Moe OW (2006) Kidney stones: pathophysiology and medical management. Lancet 367(9507):333–344
Resnick M, Pridgen DB, Goodman HO (1968) Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med 278(24):1313–1318
Smith LH (1989) The medical aspects of urolithiasis: an overview. J Urol 141(3 Pt 2):707–710
Danpure CJ (2000) Genetic disorders and urolithiasis. Urol Clin N Am 27(2):287–299
Curhan GC et al (1997) Family history and risk of kidney stones. J Am Soc Nephrol 8(10):1568–1573
Ljunghall S (1979) Family history of renal stones in a population study of stone-formers and health subjects. Br J Urol 51(4):249–252
Knoll T et al (2011) Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. J Urol 185(4):1304–1311
Garcia-Raia A, Conte A, Grases F (1991) The origin and causes of struvite stones. Int Urol Nephrol 23(6):537–542
Schey HM, Corbett WT, Resnick MI (1979) Prevalence rate of renal stone disease in Forsyth County, North Carolina during 1977. J Urol 122(3):288–291
Graves EJ, Gillum BS (1997) Detailed diagnoses and procedures, National Hospital Discharge Survey, 1995. Vital Health Stat 13(99):1–60
Kohri K et al (1991) Epidemiology of urolithiasis in the elderly. Int Urol Nephrol 23(5):413–421
Naghii MR, Hedayati M (2010) Determinant role of gonadal sex hormones in the pathogenesis of urolithiasis in a male subject—a document for male predominancy (case study). Endocr Regul 44(4):143–146
Yagisawa T et al (2001) The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 166(3):1078–1082
Lee YH et al (1992) Determinant role of testosterone in the pathogenesis of urolithiasis in rats. J Urol 147(4):1134–1138
Aihara K, Byer KJ, Khan SR (2003) Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 64(4):1283–1291
Escobar C et al (2008) Apatite induced renal epithelial injury: insight into the pathogenesis of kidney stones. J Urol 180(1):379–387
Worcester EM, Coe FL (2008) Nephrolithiasis. Prim Care 35(2):369–391
Baumann JM (1998) Stone prevention: why so little progress? Urol Res 26(2):77–81
Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98(2):e55–e60
Khan SR, Kok DJ (2004) Modulators of urinary stone formation. Front Biosci 9:1450–1482
Coe FL, Evan A, Worcester E (2005) Kidney stone disease. J Clin Invest 115(10):2598–2608
Atmani F et al (2003) Prophylaxis of calcium oxalate stones by Herniaria hirsuta on experimentally induced nephrolithiasis in rats. BJU Int 92(1):137–140
Ryall RL (1997) Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 15(3):155–164
Khan SR, Glenton PA, Byer KJ (2006) Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-l-proline. Kidney Int 70(5):914–923
Kok DJ (1997) Intratubular crystallization events. World J Urol 15(4):219–228
Lieske JC, Deganello S (1999) Nucleation, adhesion, and internalization of calcium-containing urinary crystals by renal cells. J Am Soc Nephrol 10(Suppl 14):S422–S429
Coe FL et al (2010) Three pathways for human kidney stone formation. Urol Res 38(3):147–160
Byer K, Khan SR (2005) Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 173(2):640–646
Santhosh Kumar M, Selvam R (2003) Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. J Nutr Biochem 14(6):306–313
Thamilselvan S, Khan SR, Menon M (2003) Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 31(1):3–9
Khan SR, Canales BK (2015) A unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis 43(01):109–123
Li WM et al (2009) Association of body mass index and urine pH in patients with urolithiasis. Urol Res 37(4):193–196
Iida S (1991) Effects of urinary pH and acid-base balance on the formation of calcium oxalate stone. Nippon Hinyokika Gakkai Zasshi 82(1):33–40
Wagner CA, Mohebbi N (2010) Urinary pH and stone formation. J Nephrol 23(Suppl 16):S165–S169
Coe FL et al (1980) Uric acid saturation in calcium nephrolithiasis. Kidney Int 17(5):662–668
Grover PK, Ryall RL, Marshall VR (1990) Effect of urate on calcium oxalate crystallization in human urine: evidence for a promotory role of hyperuricosuria in urolithiasis. Clin Sci (Lond) 79(1):9–15
Coe FL, Bushinsky DA (1984) Pathophysiology of hypercalciuria. Am J Physiol 247(1 Pt 2):F1–F13
Parks J, Coe F, Favus M (1980) Hyperparathyroidism in nephrolithiasis. Arch Intern Med 140(11):1479–1481
Bek-Jensen H et al (1996) Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine? Urol Res 24(2):67–71
Caudarella R, Vescini F (2009) Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment. Arch Ital Urol Androl 81(3):182–187
Minisola S et al (1989) Studies on citrate metabolism in normal subjects and kidney stone patients. Miner Electrolyte Metab 15(5):303–308
Goktas C et al (2012) The effect of citrate replacement in hypocitraturic cases on the results of SWL: a preliminary prospective randomized study. Int Urol Nephrol 44(5):1357–1362
Govaris A et al (2010) The antimicrobial effect of oregano essential oil, nisin and their combination against Salmonella Enteritidis in minced sheep meat during refrigerated storage. Int J Food Microbiol 137(2–3):175–180
Coe FL, Parks JH, Asplin JR (1992) The pathogenesis and treatment of kidney stones. N Engl J Med 327(16):1141–1152
Coe FL, Parks JH, Moore ES (1979) Familial idiopathic hypercalciuria. N Engl J Med 300(7):337–340
Mehes K, Szelid Z (1980) Autosomal dominant inheritance of hypercalciuria. Eur J Pediatr 133(3):239–242
Coe FL et al (1982) Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 72(1):25–32
Price PA, Urist MR, Otawara Y (1983) Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 117(3):765–771
Fraser J, Price P (1988) Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J Biol Chem 263(23):11033–11036
Murshed M et al (2004) Extracellular matrix mineralization is regulated locally; different roles of two Gla-containing proteins. J Cell Biol 165(5):625–630
Schurgers LJ, Cranenburg EC, Vermeer C (2008) Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 100(4):593–603
Luo G et al (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386(6620):78–81
Proudfoot D, Shanahan C (2006) Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology (Carlton) 11(5):455–461
Torres L et al (2009) Coagulation–flocculation process applied to wastewaters generated in hydrocarbon-contaminated soil washing: interactions among coagulant and flocculant concentrations and pH value. J Environ Sci Health A Tox Hazard Subst Environ Eng 44(13):1449–1456
Cranenburg EC et al (2009) Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 101(2):359–366
Cozzolino M (2009) Matrix-Gla protein and vascular calcification: the negative role of oral anticoagulant therapy. Thromb Haemost 101(4):605–606
Gao B et al (2010) Matrix Gla protein expression in NRK-52E cells exposed to oxalate and calcium oxalate monohydrate crystals. Urol Int 85(2):237–241
Khan A, Wang W, Khan SR (2014) Calcium oxalate nephrolithiasis and expression of matrix GLA protein in the kidneys. World J Urol 32(1):123–130
Yasui T et al (1999) Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27(4):255–261
Wang L et al (2000) Altered gene expression in kidneys of mice with 2,8-dihydroxyadenine nephrolithiasis. Kidney Int 58(2):528–536
Gao B et al (2007) A polymorphism of matrix Gla protein gene is associated with kidney stones. J Urol 177(6):2361–2365
Viuda-Martos M et al (2010) Antioxidant activity of essential oils of five spice plants widely used in a Mediterranean diet. Flavour Fragr J 25(1):13–19
Zuo J et al (2011) Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-l-proline-induced hyperoxaluria in the male Sprague-Dawley rats. Nephrol Dial Transplant 26(6):1785–1796
Bonventre VSV, Victoria R, Takaharu I, Norma AB, Joseph V (2006) Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290(2):F517–F529
Doyle IR, Ryall RL, Marshall VR (1991) Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon. Clin Chem 37(9):1589–1594
Grover PK, Ryall RL (1999) Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. Eur J Biochem 263(1):50–56
Boskey AL (1989) Phospholipids and calcification. In: Hukins D (ed) Calcified tissue. CRC Press, Boca Raton, pp 215–243
Webber D, Rodgers AL, Sturrock ED (2002) Synergism between urinary prothrombin fragment 1 and urine: a comparison of inhibitory activities in stone-prone and stone-free population groups. Clin Chem Lab Med 40(9):930–936
Grover PK, Ryall RL (2002) Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. Clin Sci (Lond) 102(4):425–434
Webber D et al (2006) Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation. FEBS J 273(13):3024–3037
Webber D, Rodgers AL, Sturrock ED (2007) Glycosylation of prothrombin fragment 1 governs calcium oxalate crystal nucleation and aggregation, but not crystal growth. Urol Res 35(6):277–285
Tamm I, Horsfall FL Jr (1950) Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med 74(1):106–108
Hess B (1992) Tamm–Horsfall glycoprotein–inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 20(1):83–86
Hallson PC, Rose GA (1979) Uromucoids and urinary stone formation. Lancet 1(8124):1000–1002
Rose GA, Sulaiman S (1982) Tamm–Horsfall mucoproteins promote calcium oxalate crystal formation in urine: quantitative studies. J Urol 127(1):177–179
Tang Y et al (1995) Is nephrocalcin related to the urinary derivative (bikunin) of inter-α-trypsin inhibitor? Br J Urol 76(4):425–430
Witte J et al (1982) Disturbances of selected plasma proteins in hyperdynamic septic shock. Intensive Care Med 8(5):215–222
Franck C, Pedersen JZ (1983) Trypsin-inhibitory activities of acid-stable fragments of the inter-alpha-trypsin inhibitor in inflammatory and uraemic conditions. Scand J Clin Lab Invest 43(2):151–155
Owyang C et al (1982) Pancreatic exocrine function in severe human chronic renal failure. Gut 23(5):357–361
Thogersen IB, Enghild JJ (1995) Biosynthesis of bikunin proteins in the human carcinoma cell line HepG2 and in primary human hepatocytes. Polypeptide assembly by glycosaminoglycan. J Biol Chem 270(31):18700–18709
Yoshida E et al (1994) Immunohistochemical demonstration of bikunin, a light chain of inter-alpha-trypsin inhibitor, in human brain tumors. Inflammation 18(6):589–596
Toki N, Sumi H (1982) Urinary trypsin inhibitor and urokinase activities in renal diseases. Acta Haematol 67(2):109–113
Iida S et al (1999) Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol 10(5):986–996
Bauer J (1911) Die Biologie des Kolostrums (einschliesslich Fermente). Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie 11(1):104–120
Moriyama MT, Glenton PA, Khan SR (2001) Expression of inter-alpha inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol 165(5):1687–1692
Atmani F, Khan SR (1999) Role of urinary bikunin in the inhibition of calcium oxalate crystallization. J Am Soc Nephrol 10(Suppl 14):S385–S388
Ebisuno S et al (1999) Bikunin prevents adhesion of calcium oxalate crystal to renal tubular cells in human urine. J Am Soc Nephrol 10(Suppl 14):S436–S440
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that they have no conflict of interest.
Funding
This is not a funded study.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Khan, A. Prevalence, pathophysiological mechanisms and factors affecting urolithiasis. Int Urol Nephrol 50, 799–806 (2018). https://doi.org/10.1007/s11255-018-1849-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-018-1849-2